Drugs / baltaleucel-T
baltaleucel-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02763254 | Nov 2016 → Feb 2018 | Hodgkins lymphoma, diffuse large B-cell lymphoma, post-transplant lymphoproliferative disease | Cell Medica Ltd | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01948180 | Sep 2014 → Apr 2018 | Epstein-Barr virus infection, extranodal nasal NK/T cell lymphoma | Cell Medica Ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | baltaleucel-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01948180 ↗ |
| Known as | Baltaleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990003 ↗ |
| Known as | CMD-003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990003 ↗ |
| Modality | Cell therapy | “Autologous EBV-specific T-cells” NCT01948180 ↗ |
| Route | Intravenous | “administered intravenously” NCT02763254 ↗ |